20-46037250-T-C
Variant summary
Our verdict is Benign. Variant got -18 ACMG points: 0P and 18B. BP4_ModerateBP6_Very_StrongBS1BS2
The NM_020708.5(SLC12A5):c.482-5T>C variant causes a splice region, splice polypyrimidine tract, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00991 in 1,596,084 control chromosomes in the GnomAD database, including 112 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (★★).
Frequency
Consequence
NM_020708.5 splice_region, splice_polypyrimidine_tract, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SLC12A5 | NM_020708.5 | c.482-5T>C | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | ENST00000243964.7 | |||
SLC12A5 | NM_001134771.2 | c.551-5T>C | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SLC12A5 | ENST00000243964.7 | c.482-5T>C | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | 1 | NM_020708.5 | A1 |
Frequencies
GnomAD3 genomes AF: 0.00667 AC: 1014AN: 152084Hom.: 7 Cov.: 31
GnomAD3 exomes AF: 0.00697 AC: 1656AN: 237704Hom.: 7 AF XY: 0.00755 AC XY: 969AN XY: 128322
GnomAD4 exome AF: 0.0102 AC: 14799AN: 1443882Hom.: 105 Cov.: 30 AF XY: 0.0104 AC XY: 7423AN XY: 716984
GnomAD4 genome AF: 0.00666 AC: 1013AN: 152202Hom.: 7 Cov.: 31 AF XY: 0.00646 AC XY: 481AN XY: 74404
ClinVar
Submissions by phenotype
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 03, 2023 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2024 | SLC12A5: BP4, BS1, BS2 - |
Developmental and epileptic encephalopathy, 34 Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
SLC12A5-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 21, 2024 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at